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Abstract
Purpose: The European Academy of Allergy and Clinical Immunology (EAACI) has
produced Guidelines on Allergen Immunotherapy (AIT). We sought to gauge the pre-
paredness of primary care to participate in the delivery of AIT in Europe.
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This Guideline published by the European
Academy of Allergy and Clinical Immunology
(EAACI) has drawn on data from a
systematic review of the literature, more
recent published studies and multitakeholder
expert clinical opinion. This Guideline is
aimed at healthcare professionals who are
encouraged to take the recommendations
into account in the context of delivering
clinical care. This Guideline is not a
substitute for professional clinical judgment,
which professionals need to exercise in the
context of delivering personalised
healthcare.
Methods: We undertook a mixed-methods, situational analysis. This involved a pur-
poseful literature search and two surveys: one to primary care clinicians and the
other to a wider group of stakeholders across Europe.
Results: The 10 papers identified all pointed out gaps or deficiencies in allergy care
provision in primary care. The surveys also highlighted similar concerns, particularly
in relation to concerns about lack of knowledge, skills, infrastructural weaknesses,
reimbursement policies and communication with specialists as barriers to evidence-
based care. Almost all countries (92%) reported the availability of AIT. In spite of
that, only 28% and 44% of the countries reported the availability of guidelines for
primary care physicians and specialists, respectively. Agreed pathways between spe-
cialists and primary care physicians were reported as existing in 32%-48% of coun-
tries. Reimbursement appeared to be an important barrier as AIT was only fully
reimbursed in 32% of countries. Additionally, 44% of respondents considered acces-
sibility to AIT and 36% stating patient costs were barriers.
Conclusions: Successful working with primary care providers is essential to scaling-
up AIT provision in Europe, but to achieve this, the identified barriers must be over-
come. Development of primary care interpretation of guidelines to aid patient selec-
tion, establishment of disease management pathways and collaboration with
specialist groups are required as a matter of urgency.
K E YWORD S
barriers, care pathways, educational needs, immunotherapy guidelines, primary care
1 | INTRODUCTION
The march of allergy proceeds relentlessly with up to a third of the
general population and half of young people suffering from some
manifestation of the disease at some stage in their lives.1 The most
prevalent of these conditions are atopic eczema/dermatitis, asthma
and allergic rhinitis.2-5 These result in a significant impact at the per-
sonal level because of impaired quality of life, a significant impact on
family and friends, on the healthcare system because of increased
medical costs and at a societal level because of lost productivity
through presenteeism and absenteeism.6,7 Currently, allergy is often
not well recognized and is as a result poorly managed.8 Patients seek
assistance from various sources, often involving considerable
expense and inappropriate treatment.9-11 Primary care professionals
(hereafter referred to as PCPs), these including general practitioners,
nurses and paediatricians, in some countries,12 are poorly equipped
to deal with the management of allergy, particularly the more com-
plex issues associated with AIT, due to deficiencies in undergraduate
and postgraduate training.13 Previous surveys have revealed a low
level of PCPs’ self-estimated knowledge or confidence in delivering
AIT.12 To date, there is no care system which delivers comprehen-
sive allergy care in a systematic fashion.14
In most cases, the management of allergy comprises allergen
avoidance15 and symptom alleviation by pharmacotherapy. This con-
trasts with allergen immunotherapy (AIT) which targets the
immunological basis of the disease. It can be used as complementary
to or in some cases as an alternative to pharmacotherapy in patients
for whom pharmacotherapy is not sufficiently effective or for
patients who prefer a disease-modifying treatment over chronic,
often lifelong use of symptom relieving drugs.16 AIT involves the
administration of allergen to deviate the immune response from
immediate hypersensitivity towards tolerance.17 Typically, either
injection (subcutaneous AIT, SCIT), sublingual AIT (SLIT) or oral AIT
(OIT) is used.18
The European Academy of Allergy and Clinical Immunology
(EAACI) has embarked on a process of formulating comprehensive
guidelines for AIT supported by underpinning systematic reviews on
the effectiveness, cost-effectiveness and safety of AIT for allergic
rhinitis,19 asthma,20,21 venom allergy,22 food allergy23 and the pre-
vention of allergy and allergic disorders.24 The EAACI Guidelines on
AIT should help to identify patients who are most likely to benefit
from this potentially disease-modifying treatment while also high-
lighting the current gaps in knowledge and service provision.
For comprehensive AIT services to be implemented, a system-
wide approach is needed, commencing and ultimately culminating in
primary care. This requires an understanding of primary care25 taking
into account the significant regional and national variation in configu-
ration of health services across Europe.26 AIT needs to be seen in the
wider context of overall provision of care for allergic patients, which
itself needs to be contextualized within overall healthcare provision.
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We have performed a mixed-method, situational analysis of cur-
rent provision of AIT, comprising of a literature review and surveys,
in primary care across Europe. This was done as part of the EAACI
AIT Guidelines initiative and aimed to develop a summary of the cur-
rent deficits in the service delivery of allergy care and AIT across the
whole health system. We collected survey data from: (i) GPs and (ii)
allergy stakeholders, including patient and specialist organizations.
We focused on asthma, allergic rhinitis and venom allergy; we
excluded AIT for food allergy and allergy prevention as these are
developing areas. Our aim was to summarize the different perspec-
tives on the current capabilities of primary care in the provision of
allergy management, in particular AIT. It will build on our previous
EAACI position paper.27 and work performed in the UK.28
2 | METHODS
We developed a mixed-methods approach to assess the current
capabilities of AIT provision in primary care and used our findings to
draw up a list of recommendations.
2.1 | Literature search
To inform our paper, we (DR, EA) performed a focused PubMed lit-
erature search (see Online supplement 1 for search strategy). This
was supplemented by a (UK) Royal College of General Practitioners
Discovery and Medline search. The abstracts were assessed by DR
and EA. Papers not written in English, and irrelevant papers were
rejected. The remaining papers were read in full. Due to the diversity
of papers with few recurring themes, a narrative description of the
literature search was undertaken.
2.2 | Situational analysis
We undertook a situational assessment using an online questionnaire
(see Online supplement 2) to understand the perspectives of stake-
holders: (i) general practitioners (GPs), and (ii) stakeholders (specialist
allergy societies and patient organizations) in different European
countries. We developed a draft survey, which was piloted and,
where necessary, revised. There were 12 questions for GPs and 10
questions for stakeholders (see Online supplement). A combination
of closed and open-ended questions was chosen to elicit additional
information regarding perspectives on strategies to improve uptake
of AIT in primary care. The survey was administered through the
web-based SurveyXact system. (SurveyXact, Aarhus, Denmark). Invi-
tations to participate in the survey were distributed to European
GPs via the International Primary Care Respiratory Group (IPCRG)
and World Organization of National Colleges and Associations, Eur-
ope (WONCA); to European specialist allergy societies using a list
supplied by EAACI; and to European allergy patient support group
via the EAACI patient representative contacts list. Data collection
took place between December 2016 and February 2017. Two email
reminders were sent. Data were analysed using descriptive statistics.
Answers to open-ended questions were coded using content analy-
sis, and illustrative quotes were selected (please see Online supple-
ment 3). We recorded positive answers thereby focusing on
presence of services, education, training, reimbursement and barriers.
We pooled negative and missing answers as the questionnaire did
not always permit us to make a clear distinction between both cate-
gories. We have not presented the responses from non-European
sources.
3 | RESULTS
3.1 | Literature search
A total of 59 references were obtained from the combined searches.
Of these, 36 were excluded as they provided results of clinical trials,
were guidelines or studies analysing cost-effectiveness of AIT. A
further 12 papers were duplicates. Eleven papers were thus
included; these are summarized briefly below.
One paper addressed care delivery in a generic fashion. It
described critical factors for achieving good care, using efficient pri-
mary care systems to translate service delivery into high-quality out-
comes. The authors described a combination of access, continuity
and comprehensiveness.29 A further paper addressed the variability
in allergy care provision in primary care.30 Two papers focused on
the use of specific-IgE in informing patient management as part of a
strategy to improve care.31,32
Five papers studied perception, knowledge or practice of AIT
across various specialist groups, including primary care, paediatricians
and ear, nose and throat (ENT) specialists, delivering services in pri-
mary care across a large geographical spread.33-37 These papers also
suggested that SCIT was more likely to be prescribed in specialist
care and SLIT more commonly prescribed in primary care.
One paper provided an historical description of allergy and how
care had progressed over the last 50 years. It highlighted that much
still needed to be done to understand the predisposition to atopic
disease and identifying the environmental cofactors involved in the
“allergic epidemic” and therefore targets for effective primary pre-
vention.38 The final paper identified common questions in allergy
practice gathered from delegates attending a conference on allergy
care.39
In summary, this literature review described what was already
known, namely, that there are major gaps in knowledge and skills in
the provision of allergy care, and that these are widespread and not
limited to primary care. The literature review also laid bare the pau-
city of relevant research in primary care settings.
3.2 | Situational analysis
3.2.1 | Primary care clinician survey
The GP survey yielded evaluable responses from 132 GPs of which
70 (52%) were from Europe (ie Greece, Ireland, Macedonia, Norway,
Poland, Portugal Romania Turkey, UK). The majority of these
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responses were from the UK and Romania (53 respondents).
The paucity of responses coupled with poor geographical spread led
us to create a narrative summary of our findings (online supplement
3.)
Ten per cent reported awareness of any national primary care
guidelines; 13% stated that AIT was part of general practice training
and 17% said that formal AIT training for GPs was available. 38%
stated that GPs were aware that AIT could be administered by sub-
cutaneous and sublingual routes. However, 55% felt that GPs were
competent in taking an allergy history.
The greatest barriers perceived for GPs working with AIT were a
lack of knowledge and infrastructure (both 79%), concerns about
reimbursement policies (68%), time pressures (67%) and suboptimal
communication with specialists (55%). Most (67%) respondents sta-
ted they were open to collaboration with allergy specialists. These
data strongly resonated with other published data8,13
3.2.2 | Stakeholder survey
The stakeholder survey was sent to 173 specialist allergy societies
and allergy patient support groups, with 50 responses (29%) covering
25 European countries. Where more than one set of data was
received from one country, the most positive result from that coun-
try was included. The rationale for this was to present the best-case
scenario. Table 1 gives the positive replies from the 25 European
countries to a selected series of questions. From the 36 responses
covering the European countries, 18 came from allergy societies,
three from patient groups, and 15 were from mixed origin (GPs, indi-
viduals, GP societies or not stated).
It would seem that AIT is available in most European countries
with the exception of Bosnia and Herzegovina, and Malta. The most
common location for administration was in specialist care (84%), but
in some countries, administration took place in primary care (20%) or
shared care (16%) settings. In 56% of countries there appeared to be
a national policy on AIT. The absence of a national policy did not
preclude some form of reimbursement, but countries without a
national policy were less likely to attract any form of reimbursement.
Comparing answers given to the number of question items gen-
erated, some countries clearly had a more comprehensive approach
to allergy care (ie Germany, Denmark and the UK) whereas other
countries Malta, Portugal and Ireland appeared to have given less
consideration to AIT (Table 1).
With regard to barriers to delivering care as assessed by the
stakeholders, accessibility (44%) and costs to the patient (including
time missed from work and travel costs, 36%) were viewed as the
greatest obstacles whereas safety fears (12%) were very low on the
list (Table 2).
4 | DISCUSSION
The literature review and PCP and stakeholder surveys revealed
knowledge and skills gaps coupled with nonexistent or poorly
formulated pathways of training and care. We found that there were
more specialist guidelines than primary care ones and more accredita-
tion pathways for specialists than PCPs. Given that specialists would
be training primary care colleagues and remain a vital resource, it is
important that pathways of care and shared care models are devel-
oped. It is to be noted that collaboration between PCPs and special-
ists was judged to a critical success factor in the Finnish 10 Year
Allergy Programme.40 In reality, patients will present anywhere along
a pathway of care. Most AIT is delivered by specialists41 but this
might alter with the availability of SLIT, which is easier to deliver in
the community. Adherence with AIT may be facilitated by the involve-
ment of PCPs and pharmacists and may result in cost savings, with
specific reference to minimizing time lost from work by patients.42
Combining shared care pathways with the development of relevant
competencies and capacities might increase accessibility to AIT. Tools
such as pocket guidelines may also facilitate service delivery.43
There are three key areas which need to be addressed. The first
is the development of education and training of PCPs. The second
key area is diagnosis and stratification of patients into those who
can be managed exclusively in primary care and those with more
problematic disease who need referral to specialist care. The final
area is service delivery and the monitoring of treatment effective-
ness at the patient level.
4.1 | Education and training
Our survey and other published data12 suggest that PCPs are not
trained to adequately manage allergy patients. Allergy hardly fea-
tures in most undergraduate medical curricula.13 There is little allergy
training in primary care postgraduate specialist training.41 There has
though been an assessment of training needs44 and identification of
core competencies required45 which should facilitate an educational
process. We suggest that training in allergy and AIT should be
included in all undergraduate medical curricula. Furthermore, we sug-
gest that sufficient training in allergy and AIT is included in primary
care postgraduate medical specialist training to allow the develop-
ment of core competencies in the diagnosis and management of
common allergic presentations. This would include the use and inter-
pretation of tests used to confirm the presence of sensitization and
whether or not this was relevant to the patients’ clinical state.46
Dialogue between specialist and PCPs should help to improve
knowledge and treatment pathways at a local level. The issue of
reimbursement of practitioners and patients needs to be recognized
as these issues may affect the accessibility to AIT, including those
related to travel and missing time from work.
4.2 | Diagnosis and stratification of patients
Prior to any other intervention, a secure diagnosis needs to be made.
Further, to optimize allergy management patients need to be strati-
fied, probably by disease severity, into those who can be managed
exclusively in primary care and those who need referral into special-
ist care. Characteristically, patients attending their GP or pharmacist
830 | RYAN ET AL.
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suffer from as yet undiagnosed problems. A thorough history leads
to a diagnosis or differential diagnosis. The history should guide the
request for investigations.47 To firmly establish a diagnosis, a physi-
cal examination, appropriate to the presenting complaint and investi-
gation(s) is likely to be required, although for some allergic disorders,
there may be no relevant physical finding.
According to our survey (data not shown), many GPs across Eur-
ope have access to serum specific-IgE testing; in contrast, very few
have access to skin prick testing.48 Small studies confirm that such
testing improves the ability to make a diagnosis of allergic and,
importantly, of nonallergic diseases.31,49 There is a clear rationale for
using specific-IgE tests in primary care.31,50 Further work needs to
be undertaken around the place and utility of specific-IgE in primary
care and how best to educate practitioners in the interpretation of
results in the clinical context.46 This has been identified as a pressing
research need by the IPCRG.51
4.3 | Service delivery and monitoring
Developing vertically integrated care pathways might be one way of
developing a process for service delivery.52 Such a pathway could
include community pharmacists to aid in identification of patients;
they may also be able to play a role in promoting adherence. The
patient journey often commences with the community pharmacist,
providing a rationale for including them in any proposed care.53 A fur-
ther option to be considered, particularly where specialists are scarce,
is the development of a network of GPs with specialist interests
(GPwSIs) whose remit would include service provision and local educa-
tional initiatives working in close collaboration with specialist men-
tors.54,55 This would also present an opportunity to develop a network
of care to establish clear communication and shared decision-making.
4.4 | Strengths and limitations of the surveys
An exploratory analysis is presented, the first of its kind. The study
focuses on the views of primary care clinicians and relevant stake-
holders concerning allergy care and AIT and on barriers in this field.
The main limitation of this study is the low response rate, particu-
larly in the GP survey. It was difficult to identify appropriate respon-
dents for each country. A substantial number of stakeholder
responses came neither from patient groups nor from allergy soci-
eties, and thus, responses may not be completely representative of
the situation in specific countries although together they provide a
reasonable description of the reality across Europe. Finally, although
the surveys give a good impression of available services and barriers
for GPs in Europe, pooling negative and missing responses and clas-
sifying the latter as negative limit the accuracy of the outcome.
4.5 | Looking ahead
Based on our findings, we have made some recommendations (see
Table 3). Although our findings seem somewhat discouraging, there is
room for optimism. Clinical trials in AIT have been successfullyT
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carried out in primary care, demonstrating proof of concept.56,57 It is
of further interest that in a real-life study of AIT adherence carried
out in the Netherlands that adherence and persistence was higher
amongst patients of GPs than those of allergists or other specialists.58
The development of pathways of care should facilitate the delivery of
high-quality effective services and improve patient selection. These
TABLE 3 Recommendations, barriers and facilitators
Key Recommendations Barriers Facilitators Key References
1. Teaching in allergy and AIT
should be included in all
undergraduate medical
curricula.
• Low priority on educational
agenda.
• Inadequate skills and knowl-
edge in the medical work-
force.
• Inadequate representation of
Allergy in general Undergrad-
uate or Postgraduate
curricula.
• Allergy campaigns to raise
awareness to governments
and patients.
• Workforce remodelling with
collaborative relationships
with specialists.
• Clinical system-wide leader-
ship with investment in
education and training.
Potter, 2009.59 Campbell
201538
Shehata 200613
2. There should be sufficient
training in allergy and AIT
included in primary care
postgraduate medical specialist
training to allow the
development of core
competencies in the diagnosis
and management of common
allergic presentations.
• Low priority on political
agenda with lack of treatment
prioritization.
• Inadequate health economics
data and population-based
outcomes.
• Inadequate representation of
Allergy in general Undergrad-
uate or Postgraduate
curricula.
• Workforce remodelling with
collaborative relationships
with specialists.
• Clinical system-wide leader-
ship with investment in
education and training.
Campbell 2015,38 Tan 2014,39
Eigenmann 201360
Wallengren 201145
3. Primary care workers should
have access to specific-IgE
testing and, if required, have
assistance in interpretation of
results.
• Inadequate skills and knowl-
edge in the medical work-
force.
• Poor understanding of diag-
nostic tests in primary care
used in the assessment and
diagnosis of allergy.
• Lack of clear care pathways
and referral criteria.
• Heterogeneous reimburse-
ment policies for investiga-
tions and their administration.
• Clinical system-wide leader-
ship with investment in edu-
cation and training.
• System-wide healthcare deliv-
ery mirroring patient journey
from pharmacists through to
specialists.
• Harmonization of reimburse-
ment policies.
Pelone 2013.29 Hansen
2010,30 Dranitsaris 2014.42
Ellis 2012.44 Bousquet 201561
4. There is a need to develop and
implement vertically integrated
care pathways to improve
delivery of allergy care and
AIT. This could include clinical
decision support systems. It
may involve the development
of intermediate level GPs with
a specialist interest in allergy.
• Lack of clear care pathways
and referral criteria.
• Inadequate health economics
data and population-based
outcomes.
• Heterogeneous reimburse-
ment policies for products
and their administration.
• Allergy campaigns to raise
awareness to governments
and patients.
• System-wide healthcare deliv-
ery mirroring patient journey
from pharmacists through to
specialists.
• Practice nurses involved in
delivery of care, under super-
vision, allowing flexibility of
approach delivering care clo-
ser to home.
Diwakar 2017.14 Smith 2009.47
Fromer 2014.50, Bousquet
2016.63 Yao 2015, Flokstra -
de Blok 2017.64
Ryan 200554
Yao62
5. Develop specific
recommendations to aid
identification, stratification and
referral criteria to enable
effective referrals from primary
or specialist care.
• Low priority on political
agenda with lack of treatment
prioritization.
• Inadequate skills and knowl-
edge in the medical work-
force.
• Lack of clear care pathways
and referral criteria.
• Workforce remodelling with
collaborative relationships
with specialists.
Haahtela 200840
Ryan 201712
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will vary from health system to health system depending on existing
configuration, but are likely to have similar themes. Such pathways
would aim to establish a register of those who had received AIT to
facilitate identification of type and severity of side-effects as well as
permit the assessment of effectiveness of AIT in different patient
types which would ultimately aid in patient selection. This would be
facilitated by the development of a template which would permit uni-
formity of coding and clinical parameters entered. This should incor-
porate a mechanism whereby primary care can report safety issues
and adverse effects via a web-based registry system. In addition, net-
work of care with specialists and primary care professionals needs to
be developed to establish clear communication and shared decision-
making. If, as is happening in some countries, PCPs commence
immunotherapy without specialist referral, they should ensure that
the products used have proven safety and efficacy.
5 | CONCLUSIONS
We have undertaken this work to explore how the EAACI Guidelines
on Allergen Immunotherapy for the prevention and management of
allergic conditions might be implemented in primary care. The find-
ings from this mixed-methods evaluation strongly suggest that Euro-
pean primary care providers are suboptimally positioned to identify
and manage those who are most likely to benefit from AIT. We have
identified a number of important barriers—including educational and
training, infrastructural and financial—that need to be overcome in
order to scale up AIT delivery across Europe. In order to encourage
the successful adoption of AIT as a mainstream therapy, there needs
to be wide spread publicity concerning its effectiveness. Healthcare
provision has great heterogeneity across Europe: the generic recom-
mendations made in this paper will therefore need to be interpreted
and tailored in line with local healthcare policies and priorities. Com-
missioners of health services and politicians need to be made aware
of potential benefits and ultimately cost savings in line with the tri-
ple aim of health care: better patient experience, improving the
health of populations and reducing the cost of health care.
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